hfg54

THCP is a recently discovered cannabinoid that’s found at very low levels in some strains of marijuana, and can be produced in a laboratory by altering legal hemp-derived CBD. It was found accidentally by Italian researchers in 2019 during analysis of a particular marijuana strain. The full name for THCP is delta-9-tetrahydrocannabiphorol, which is sometimes shortened to delta 9 THCP or THC-heptyl. Abbreviations include THCP, THC-P, and THCp. One retailer calls it delta-p. After the smashing commercial success of delta 8 THC, the cannabis industry has found a variety of hemp-derived cannabinoids capable of competing with the delta 9 THC in traditional marijuana. These cannabinoids—delta 8, delta 10 THC, HHC, and THC-O—are all popular in the diverse cannabis marketplace, and THCP is ready to join them. While THCP may provide a potent new high for recreational users, it could also offer new therapeutic benefits for medical patients. Researchers have barely begun to explore the potential of THCP. THCP is a naturally occurring phytocannabinoid found in cannabis and an analog of THC, the compound responsible for most cannabis psychoactivity. Discovered only in late 2019 by a team of Italian researchers, THCP is one of 120 (or more) cannabinoids found to date in the cannabis plant, with many more potentially awaiting discovery. However, THCP is causing a particular stir in the cannabis community. The researchers found evidence suggesting that THCP may have a more pronounced impact on a cannabis strains’ psychoactivity than THC itself. This article dives into the limited information we have on this newly discovered cannabinoid.

What is THCV? Tetrahydrocannabivarin, or THCV, is a psychoactive cannabinoid found most prevalently in Sativa strains of cannabis. It is known to produce a more motivated, alert and energizing feeling of euphoria. For this reason, it is often recommended for daytime or any time when functionality is important. THCV relieves stress and research shows it can help to reduce or even prevent anxiety and panic attacks. For this reason, it plays an important role in the treatment of post-traumatic-stress-disorder (PTSD). It is also neuroprotective, so it is ideal for treating conditions such as Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis. Unlike THC, THCV works to suppress the appetite so it is not recommended for patients suffering from cachexia or anorexia nervosa. High-THCV cannabis strains This list is by no means comprehensive, but it includes strains best known for their tendency toward higher-than-average THCV contents. These strains can be consumed in flower form or they can be processed into extracts, oils, and edibles for a higher concentration of cannabinoids. A few of the strains below, like Doug’s Varin and Pineapple Purps, were specially bred to contain higher levels of THCV. Again, be sure to steer your choices toward African sativas as they tend to contain the most THCV.

cas: 1606994-55-1 Elamipretide (TFA) Molecular Formula: C34H50F3N9O7 Formula Weight: 753.83 CAS No.: 1606994-55-1

cas: 736992-21-5 Elamipretide CBNumber: CB92708860 Chemical Name: Elamipretide Molecular Formula: C32H49N9O5 Formula Weight: 639.79 CAS No.: 736992-21-5

CAS: 7499-19-6 Benzenepropanamide CBNumber: CB23250567 Chemical Name: Benzenepropanamide, a-methyl- Molecular Formula: C10H13NO Formula Weight: 163.22 CAS No.: 7499-19-6

cas: 403848-57-7 Caspase-9 Inhibitor III cas: 403848-57-7 AC-LEHD-CMK Ac-Leu-Glu-His-Asp-chloromethylketone Molecular Formula: C24H35ClN6O9 Formula Weight: 587.02 CAS No.: 403848-57-7

cas: 72957-38-1 DynorphinA(1-13) Molecular Formula: C75H126N24O15 Formula Weight: 1603.95 CAS No.: 72957-38-1

cas: 1321-67-1 naphthol 2-Naphthol Naphthalene Naphthol is an organic compound derived from naphthalene. It is commonly found in dyes used for textiles and also used in many other areas of manufacturing goods. Naphthalene is a nasal carcinogen, inducing respiratory adenomas in male and olfactory neuroblastomas in female rats, respectively. The reasons for the site and sex-specific tumorigenic response are unknown. Naphthalene is bioactivated to electrophilic metabolites; cytotoxicity followed by regenerative cell proliferation is likely involved in the tumorigenic response. To examine sex differences in the acute nasal response to naphthalene, male and female F344 rats were nose-only exposed to 0, 1, 3, 10, or 30 ppm naphthalene vapor for 4 or 6 h. Following exposure, respiratory/transitional mucosa (RTM) and olfactory mucosa (OM) were isolated and analyzed for markers of oxidant/electrophilic stress and/or toxicity, including reduced/oxidized glutathione levels (GSH/GSSG), mRNA levels of electrophile-responsive genes, and epithelial cytoxicity (as measured by membrane permeability to ethidium homodimer-1). Naphthalene caused significant depletion of GSH in RTM and OM with no increase in GSSG. Cytotoxicity was apparent at concentrations of 15 and 30 ppm. No consistent sex differences were observed in these responses. Sex differences were observed in the induction of antielectrophilic genes in OM: glutamyl cysteine ligase (catalytic subunit) (Gclc), NADPH quinone oxidase 1 (Nqo1), and heme oxygenase 1 (Hmox1) were all induced to a greater extent in the male OM compared with the female. No consistent sex differences were observed in the RTM. Although the mechanism of the sex difference in the RTM adenoma response remains enigmatic, sex differences in the induction of antioxidant/electrophile-responsive genes may contribute to the heightened sensitivity of the female OM to the carcinogenic effects of naphthalene.

cas: 2709672-58-0 4F-ADB 4F-MDMB-PINACA CBNumber: CB210987337 Chemical Name: 2709672-58-0 Molecular Formula: C15H19N3O3 Formula Weight: 289.34 CAS No.: 2709672-58-0

cas: 1659305-78-8 YAP-TEAD Inhibitor 1 CBNumber: CB24656621 Chemical Name: YAP-TEAD Inhibitor 1 Molecular Formula: C93H144ClN23O21S2 Formula Weight: 2019.86 CAS No.: 1659305-78-8

cas: 987-78-0 CDP-choline Citicoline Acid Cytidine diphosphate choline CDP-choline is a nootropic compound that is essentially a prodrug for both choline and uridine, conferring both of those molecules to the body following oral ingestion of CDP-Choline. Specifically, the CDP-choline dissociates into choline and cytidine, with the cytidine then converting into uridine. CDP-choline is one of the three choline-containing phospholipids that can be orally supplemented (the other two being Alpha-GPC and phosphatidylcholine). This supplement is catered towards preventing or treating memory impairments associated with aging due to the fact that both of the molecules it confers are neuroprotective and potentially enhance learning. While it appears to be more effective than phosphatidylcholine (PC) at this role, in part due to also increasing PC synthesis in the brain, its potency is somewhat comparable to that of Alpha-GPC. CDP-choline has some other potential uses in relation to cognition. It is commonly used as a memory enhancer in youth, but despite some rodent studies suggesting that this is possible with oral CDP-choline, there are no human studies in youth at this point in time. One study has noted an increase in attention with low dose CDP-choline (which needs to be replicated), and CDP-choline may have roles as an anti-addictive compound against both cocaine and (preliminary evidence suggests) food as well. What else is CDP-Choline known as? Note that CDP-Choline is also known as:Citicholine Cytidine Diphosphocholine CDP-Choline should not be confused with:Choline (CDP-choline contains some choline but is not exclusively choline) Uridine (similar in function to CDP-choline) Dosage information Medical disclaimer Standard dosing of CDP-choline is to take 500-2,000 mg in two divided doses (of 250-1,000 mg) usually separated by 8-12 hours, although a single daily dose is also sometimes used. A single dose of 4,000 mg does not appear to affect the blood any differently than 2,000 mg, and so it is not necessary to take such a high dose. There are some properties, such as attention-promoti

cas: 33818-15-4 CDP-Choline Citicoline nootropics Citicoline (INN), also known as cytidine diphosphate-choline (CDP-Choline) or cytidine 5'-diphosphocholine is an intermediate in the generation of phosphatidylcholine from choline, a common biochemical process in cell membranes. Citicoline is naturally occurring in the cells of human and animal tissue, in particular the organs.

cas: 135463-81-9 Coluracetam Coluracetam (INN; development code BCI-540; formerly MKC-231) is a purported nootropic agent of the racetam family.[1] It is contains a chemical group that is a bioisostere of the 9-amino-tetrahydroacridine family. It was initially developed and tested by the Mitsubishi Tanabe Pharma Corporation for Alzheimer's disease. After the drug failed to reach endpoints in its clinical trials it was in-licensed by BrainCells Inc for investigations into major depressive disorder (MDD), which was preceded by being awarded a "Qualifying Therapeutic Discovery Program Grant" by the state of California.[2] Findings from phase IIa clinical trials have suggested that it would be a potential medication for comorbid MDD with generalized anxiety disorder (GAD).[3] BrainCells Inc is currently[when?] out-licensing the drug for this purpose.[4][full citation needed] It may also have potential use in prevention and treatment of ischemic retinopathy and retinal and optic nerve injury.[medical citation needed] Coluracetam has been shown to reverse the loss of choline acetyltransferase production in the medial septal nucleus of rats exposed to phencyclidine (PCP), and is considered a potential therapeutic drug for schizophrenia.[5] Coluracetam (MKC-231) is a synthetic racetam drug purported to be a nootropic compound. It does not have a large body of evidence investigating it, but the mechanisms of action (as well as structure) appear to be very distinct from other racetam compounds like Piracetam or Aniracetam. Coluracetam appears to interact with a process known as high affinity choline uptake (HACU for short), which is the rate-limiting step of drawing choline into a neuron for synthesis into the neurotransmitter acetylcholine. Increasing the HACU rate appears to increase the activity of cholinergic neurons, so it is a desired target for cognitive enhancement. Interventions in rats (as there is no human evidence currently) support the usage of coluracetam at very low oral doses to preserve HACU that is otherwise impaired by the use of research drugs that are known to impair HACU. The limited evidence looking at the inherent effects of coluracetam on the HACU of normal neurons has failed to find any significant interaction. Coluracetam has also been noted to associate with choline transporters physically, but it is not known exactly what it does once associated. Overall, there is currently insufficient evidence to support the usage of coluracetam for cognitive enhancement. Further studies are needed to see if it has a therapeutic role in instances where HACU may be impaired (such as Alzheimer's disease). What else is Coluracetam known as? Note that Coluracetam is also known as:MKC-231 BCI-540 2-(2-oxypyrrolidin-1-yl)-N-(2 3-dimethyl-5 6 7 8-tetrahydrofuro(2 3-b)quinolin-4-yl)acetoamide

cas: 1890208-58-8 Compound 7P Strongest Nootropic IS COMPOUND 7P A BRAIN REGENERATIVE COMPOUND? The neurons in the adult central nervous system (CNS) fail to regenerate axons after injury, which accounts in part for the poor functional recovery in patients with traumatic and neurodegenerative diseases (1). The failure of axon regeneration is attributable to a growth-inhibiting environment involving myelin-associated inhibitors (Nogo-A, myelin-associated glycoprotein, and oligodendrocyte/myelin glycoprotein) and glial scar at the injury site.However, neutralizing and/or removing such inhibitory factors are insufficient to promote long-distance axon regeneration (1).‍ In this study, in an effort to discover new pharmacological modalities to aid in axon regeneration, we employed phenotypic cell-based screens that allow visual assessment and quantitative measurement of neurite outgrowth in vitro. The phenotypic screening campaign and chemical modification efforts led to identification of compound 7p that enhances neurite outgrowth in cultured primary neurons derived from the hippocampus, cerebral cortex, and retina and that induces optic nerve regeneration in an animal model of optic nerve injury. Although it needs to be determined how the compound stimulates axon growth in vivo, our results should provide further insight into the treatment strategies for clinical conditions associated with a loss of axon. Another report using phenotypic cell-based screen of chemical libraries and structure-activity-guided optimization resulted in the identification of compound 7p which promotes neurite outgrowth of cultured primary neurons derived from the hippocampus, cerebral cortex, and retina. in an animal model of optic nerve injury, compound 7p was shown to induce growth of gap-43 positive axons, indicating that the in vitro neurite outgrowth activity of compound 7p translates into stimulation of axon regeneration in vivo.further optimization of compound 7p and elucidation of the mechanisms by which it elicits axon regeneration in vivo will provide a rational basis for fut Compound 7p (2-[(2-methoxyphenyl)[(4-methyl phenyl) sulfonyl] amino]-N-(4-methoxy-3-pyridinyl) acetamide) showed the highest activity against cervical cancer cells. In a nude mouse xenograft model inoculated with HeLa cells, 7p showed dose-dependent inhibition of cervical tumour growth. Histopathological examination of excised tumour-bearing tissues showed that 7p improved the microstructure in a dose-dependent manner. Compound 7p also increased the proportions of HeLa cells in G0/G1 and S-phase and significantly decreased that of G2/M-phase. The effects of 7p on C-caspase-3, C-caspase-9, Bcl-2 and Bax expression in HeLa cells were also determined. Compound 7p was developed as one in series of compounds with the aim of identifying dual-acting thromboxane receptor antagonist/synthase inhibitors. In fact compound 7p shows selectivity for prostaglandin I2 synthase (PTGIS, CYP8A1) over thromboxane synthase (CYP5A1).

CAS: 56786-63-1 5α-hydroxy Laxogenin CBNumber: CB92657041 Chemical Name: 5α-hydroxy Laxogenin Molecular Formula: C27H42O5 Formula Weight: 446.62 CAS No.: 56786-63-1 5-alpha hydroxy laxogenin is a plant-derived polyhydroxylated derivative of 5a-cholestane, similar to anabolic steroids in mammals or insect ecdysteroids. 5-alpha-hydroxy-laxogenin is derived from a synthetic version of laxogenin. Laxogenin itself belongs to a family of compounds that are more commonly referred to as brassinosteroids. Furthermore, laxogenin has been found in plants and drives growth throughout the plant itself. In a study conducted by Esposito et. Al, rodents were given a similar compound, 28-Homobrassinolide (HB) to see what effects it would have on lean body mass. Rodents were given either 20 mg or 60 mg of HB over a 24 day period. The study concluded that the 20 mg group had a 7% increase in lean muscle and a 3.9% reduction in body fat while the 60 mg group had a 14.2% increase in lean muscle and a 4.9% reduction in body fat. These results were found through the use of a DEXA scan Additionally, HB use was also associated with an increase in strength without additional training, as the rats exhibited a 6.7 percent increase in grip strength of the lower extremities. Brassinosteroids are considered a phytohormone that plays a role in plant growth and development. Additionally, brassinosteroids are incredibly similar to various animal hormones in the way that they affect various aspects of growth and synthesization such as cell elongation, cell division, immunity, and reproduction